Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393206 | 0.95 | POLB (0.66) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL12978565 | 0.93 | POLB (0.64) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL9717433 | 0.90 | POLB (0.68) | NPC1RAB9APOLBALDH1A1MAPK1 | |
| SCHEMBL5636368 | 0.89 | NPC1 (0.62) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL8989702 | 0.84 | NPC1 (0.62) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL6378992 | 0.84 | NPC1 (0.62) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL19133492 | 0.84 | NPC1 (0.67) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL9862834 | 0.83 | HDAC3 (0.61) | NPC1RAB9APOLBHDAC6NAMPT | |
| SCHEMBL30074578 | 0.83 | HPGD (0.68) | NPC1RAB9APOLBACKR3TMEM97 | |
| SCHEMBL30418256 | 0.83 | SIGMAR1 (0.75) | NPC1RAB9APOLBACKR3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013048811-A1 | IMAGING AND RADIOTHERAPY METHODS FOR TUMOUR STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048811-A1 | IMAGING AND RADIOTHERAPY METHODS FOR TUMOUR STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2349351-A2 | IMAGING AND RADIOTHERAPY METHODS | GE Healthcare Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | NPC1 1239/4885RAB9A 2097/4885POLB 1591/4885 |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | NPC1 1239/4885RAB9A 2097/4885POLB 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.